Identification of key functional residues in the active site of human beta 1, 4-Galactosyltransferase 7

a major enzyme in the glycosaminoglycan synthesis pathway

Ibtissam Talhaoui, Catherine Bui, Rafael Oriol, Guillermo Mulliert, Sandrine Gulberti, Patrick Netter, Michael W. H. Coughtrie, Mohamed Ouzzine, Sylvie Fournel-Gigleux

    Research output: Contribution to journalArticle

    15 Citations (Scopus)

    Abstract

    Glycosaminoglycans (GAGs) play a central role in many pathophysiological events, and exogenous xyloside substrates of beta 1,4-galactosyltransferase 7 (beta 4GalT7), a major enzyme of GAG biosynthesis, have interesting biomedical applications. To predict functional peptide regions important for substrate binding and activity of human beta 4GalT7, we conducted a phylogenetic analysis of the beta 1,4-galactosyltransferase family and generated a molecular model using the x-ray structure of Drosophila beta 4GalT7-UDP as template. Two evolutionary conserved motifs, (DVD165)-D-163 and (221)FWGWGREDDE(230), are central in the organization of the enzyme active site. This model was challenged by systematic engineering of point mutations, combined with in vitro and ex vivo functional assays. Investigation of the kinetic properties of purified recombinant wild-type beta 4GalT7 and selected mutants identified Trp(224) as a key residue governing both donor and acceptor substrate binding. Our results also suggested the involvement of the canonical carboxylate residue Asp(228) acting as general base in the reaction catalyzed by human beta 4GalT7. Importantly, ex vivo functional tests demonstrated that regulation of GAG synthesis is highly responsive to modification of these key active site amino acids. Interestingly, engineering mutants at position 224 allowed us to modify the affinity and to modulate the specificity of human beta 4GalT7 toward UDP-sugars and xyloside acceptors. Furthermore, the W224H mutant was able to sustain decorin GAG chain substitution but not GAG synthesis from exogenously added xyloside. Altogether, this study provides novel insight into human beta 4GalT7 active site functional domains, allowing manipulation of this enzyme critical for the regulation of GAG synthesis. A better understanding of the mechanism underlying GAG assembly paves the way toward GAG-based therapeutics.

    Original languageEnglish
    Pages (from-to)37342-37358
    Number of pages17
    JournalJournal of Biological Chemistry
    Volume285
    Issue number48
    Early online date14 Sep 2010
    DOIs
    Publication statusPublished - 26 Nov 2010

    Keywords

    • Amino acid
    • Enzyme kinetics
    • Protein linkage region
    • Galactosyltransferase
    • Crystal structure
    • Enzyme mutation
    • Glycosaminoglycan
    • Proteoglycan synthesis
    • Xyloside

    Cite this

    Talhaoui, Ibtissam ; Bui, Catherine ; Oriol, Rafael ; Mulliert, Guillermo ; Gulberti, Sandrine ; Netter, Patrick ; Coughtrie, Michael W. H. ; Ouzzine, Mohamed ; Fournel-Gigleux, Sylvie. / Identification of key functional residues in the active site of human beta 1, 4-Galactosyltransferase 7 : a major enzyme in the glycosaminoglycan synthesis pathway. In: Journal of Biological Chemistry. 2010 ; Vol. 285, No. 48. pp. 37342-37358.
    @article{371e2d8829dc428088e640555ea0edb2,
    title = "Identification of key functional residues in the active site of human beta 1, 4-Galactosyltransferase 7: a major enzyme in the glycosaminoglycan synthesis pathway",
    abstract = "Glycosaminoglycans (GAGs) play a central role in many pathophysiological events, and exogenous xyloside substrates of beta 1,4-galactosyltransferase 7 (beta 4GalT7), a major enzyme of GAG biosynthesis, have interesting biomedical applications. To predict functional peptide regions important for substrate binding and activity of human beta 4GalT7, we conducted a phylogenetic analysis of the beta 1,4-galactosyltransferase family and generated a molecular model using the x-ray structure of Drosophila beta 4GalT7-UDP as template. Two evolutionary conserved motifs, (DVD165)-D-163 and (221)FWGWGREDDE(230), are central in the organization of the enzyme active site. This model was challenged by systematic engineering of point mutations, combined with in vitro and ex vivo functional assays. Investigation of the kinetic properties of purified recombinant wild-type beta 4GalT7 and selected mutants identified Trp(224) as a key residue governing both donor and acceptor substrate binding. Our results also suggested the involvement of the canonical carboxylate residue Asp(228) acting as general base in the reaction catalyzed by human beta 4GalT7. Importantly, ex vivo functional tests demonstrated that regulation of GAG synthesis is highly responsive to modification of these key active site amino acids. Interestingly, engineering mutants at position 224 allowed us to modify the affinity and to modulate the specificity of human beta 4GalT7 toward UDP-sugars and xyloside acceptors. Furthermore, the W224H mutant was able to sustain decorin GAG chain substitution but not GAG synthesis from exogenously added xyloside. Altogether, this study provides novel insight into human beta 4GalT7 active site functional domains, allowing manipulation of this enzyme critical for the regulation of GAG synthesis. A better understanding of the mechanism underlying GAG assembly paves the way toward GAG-based therapeutics.",
    keywords = "Amino acid , Enzyme kinetics, Protein linkage region, Galactosyltransferase, Crystal structure, Enzyme mutation, Glycosaminoglycan, Proteoglycan synthesis, Xyloside",
    author = "Ibtissam Talhaoui and Catherine Bui and Rafael Oriol and Guillermo Mulliert and Sandrine Gulberti and Patrick Netter and Coughtrie, {Michael W. H.} and Mohamed Ouzzine and Sylvie Fournel-Gigleux",
    year = "2010",
    month = "11",
    day = "26",
    doi = "10.1074/jbc.M110.151951",
    language = "English",
    volume = "285",
    pages = "37342--37358",
    journal = "Journal of Biological Chemistry",
    issn = "0021-9258",
    publisher = "American Society for Biochemistry and Molecular Biology",
    number = "48",

    }

    Talhaoui, I, Bui, C, Oriol, R, Mulliert, G, Gulberti, S, Netter, P, Coughtrie, MWH, Ouzzine, M & Fournel-Gigleux, S 2010, 'Identification of key functional residues in the active site of human beta 1, 4-Galactosyltransferase 7: a major enzyme in the glycosaminoglycan synthesis pathway', Journal of Biological Chemistry, vol. 285, no. 48, pp. 37342-37358. https://doi.org/10.1074/jbc.M110.151951

    Identification of key functional residues in the active site of human beta 1, 4-Galactosyltransferase 7 : a major enzyme in the glycosaminoglycan synthesis pathway. / Talhaoui, Ibtissam; Bui, Catherine; Oriol, Rafael; Mulliert, Guillermo; Gulberti, Sandrine; Netter, Patrick; Coughtrie, Michael W. H.; Ouzzine, Mohamed; Fournel-Gigleux, Sylvie.

    In: Journal of Biological Chemistry, Vol. 285, No. 48, 26.11.2010, p. 37342-37358.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Identification of key functional residues in the active site of human beta 1, 4-Galactosyltransferase 7

    T2 - a major enzyme in the glycosaminoglycan synthesis pathway

    AU - Talhaoui, Ibtissam

    AU - Bui, Catherine

    AU - Oriol, Rafael

    AU - Mulliert, Guillermo

    AU - Gulberti, Sandrine

    AU - Netter, Patrick

    AU - Coughtrie, Michael W. H.

    AU - Ouzzine, Mohamed

    AU - Fournel-Gigleux, Sylvie

    PY - 2010/11/26

    Y1 - 2010/11/26

    N2 - Glycosaminoglycans (GAGs) play a central role in many pathophysiological events, and exogenous xyloside substrates of beta 1,4-galactosyltransferase 7 (beta 4GalT7), a major enzyme of GAG biosynthesis, have interesting biomedical applications. To predict functional peptide regions important for substrate binding and activity of human beta 4GalT7, we conducted a phylogenetic analysis of the beta 1,4-galactosyltransferase family and generated a molecular model using the x-ray structure of Drosophila beta 4GalT7-UDP as template. Two evolutionary conserved motifs, (DVD165)-D-163 and (221)FWGWGREDDE(230), are central in the organization of the enzyme active site. This model was challenged by systematic engineering of point mutations, combined with in vitro and ex vivo functional assays. Investigation of the kinetic properties of purified recombinant wild-type beta 4GalT7 and selected mutants identified Trp(224) as a key residue governing both donor and acceptor substrate binding. Our results also suggested the involvement of the canonical carboxylate residue Asp(228) acting as general base in the reaction catalyzed by human beta 4GalT7. Importantly, ex vivo functional tests demonstrated that regulation of GAG synthesis is highly responsive to modification of these key active site amino acids. Interestingly, engineering mutants at position 224 allowed us to modify the affinity and to modulate the specificity of human beta 4GalT7 toward UDP-sugars and xyloside acceptors. Furthermore, the W224H mutant was able to sustain decorin GAG chain substitution but not GAG synthesis from exogenously added xyloside. Altogether, this study provides novel insight into human beta 4GalT7 active site functional domains, allowing manipulation of this enzyme critical for the regulation of GAG synthesis. A better understanding of the mechanism underlying GAG assembly paves the way toward GAG-based therapeutics.

    AB - Glycosaminoglycans (GAGs) play a central role in many pathophysiological events, and exogenous xyloside substrates of beta 1,4-galactosyltransferase 7 (beta 4GalT7), a major enzyme of GAG biosynthesis, have interesting biomedical applications. To predict functional peptide regions important for substrate binding and activity of human beta 4GalT7, we conducted a phylogenetic analysis of the beta 1,4-galactosyltransferase family and generated a molecular model using the x-ray structure of Drosophila beta 4GalT7-UDP as template. Two evolutionary conserved motifs, (DVD165)-D-163 and (221)FWGWGREDDE(230), are central in the organization of the enzyme active site. This model was challenged by systematic engineering of point mutations, combined with in vitro and ex vivo functional assays. Investigation of the kinetic properties of purified recombinant wild-type beta 4GalT7 and selected mutants identified Trp(224) as a key residue governing both donor and acceptor substrate binding. Our results also suggested the involvement of the canonical carboxylate residue Asp(228) acting as general base in the reaction catalyzed by human beta 4GalT7. Importantly, ex vivo functional tests demonstrated that regulation of GAG synthesis is highly responsive to modification of these key active site amino acids. Interestingly, engineering mutants at position 224 allowed us to modify the affinity and to modulate the specificity of human beta 4GalT7 toward UDP-sugars and xyloside acceptors. Furthermore, the W224H mutant was able to sustain decorin GAG chain substitution but not GAG synthesis from exogenously added xyloside. Altogether, this study provides novel insight into human beta 4GalT7 active site functional domains, allowing manipulation of this enzyme critical for the regulation of GAG synthesis. A better understanding of the mechanism underlying GAG assembly paves the way toward GAG-based therapeutics.

    KW - Amino acid

    KW - Enzyme kinetics

    KW - Protein linkage region

    KW - Galactosyltransferase

    KW - Crystal structure

    KW - Enzyme mutation

    KW - Glycosaminoglycan

    KW - Proteoglycan synthesis

    KW - Xyloside

    U2 - 10.1074/jbc.M110.151951

    DO - 10.1074/jbc.M110.151951

    M3 - Article

    VL - 285

    SP - 37342

    EP - 37358

    JO - Journal of Biological Chemistry

    JF - Journal of Biological Chemistry

    SN - 0021-9258

    IS - 48

    ER -